权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Neonatal Opioid Screening Using Aptamers and Compensated Interferometry

使用适体和补偿干涉测量法进行新生儿阿片类药物筛查

基本信息

批准号：
10226376
负责人：
George W Jackson
金额：
$ 55.99万
依托单位：
BASE PAIR BIOTECHNOLOGIES, INC.
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-03-01 至 2023-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10226376
关键词：
Address Affect Affinity Archives Base Pairing Binding Biological Assay Biotechnology Birth Blinded Blood capillaries Buprenorphine Cessation of life Clinic Clinical Collaborations Computer software Continuous Intravenous Infusion Country DNA Data Analyses Development Devices Diagnostic Drug Prescriptions Early Intervention Engineering Epidemic Fentanyl Frequencies Goals Gold Health Hospitals Hour Hydrocodone Incidence Individual Infant Infrastructure Interferometry Intervention Label Laboratories Legal patent Libraries Mass Spectrum Analysis Measurement Medical Medical Device Methadone Methodology Methods Monitor Morphine Neonatal Neonatal Abstinence Syndrome Neurologic Effect Newborn Infant Noise Operative Surgical Procedures Opioid Optical Readers Optics Overdose Oxycodone Pain Pain management Patients Performance Pharmaceutical Preparations Phase Positioning Attribute Probability Protocols documentation Randomized Rapid screening Reader Readiness Rest Risk Sampling Scientist Signal Transduction Small Business Innovation Research Grant Specificity Symptoms Syndrome Technology Testing Training Translating Translations Treatment Cost United States Universities Urine Work addiction aptamer assay development base carfentanil clinically relevant commercialization cost design detection limit economic impact experience improved instrument laboratory experience nanolitre nanomolar neonate novel operation opioid abuse opioid epidemic opioid use pain reduction patient population point of care prescription opioid programs prototype screening social success urinary

项目摘要

Project Summary/Abstract The United States is experiencing an opioid epidemic of unprecedented scope. More than 6 out of 10 drug overdoses are now opioid-related, resulting in ~90 deaths/day. The economic impact of the epidemic has been estimated to exceed $75B/year, primarily from health and social costs related to prescription opioid use [Pain Med. 2011; 12(4):657-67. 2013; 14(10):1534-47]. New legislative actions are likely to be taken to address the crisis. Newborn Abstinence Syndrome, which results from maternal opioid drug use prior to birth, is a serious condition that afflicts approximately 6% of all neonates born today in the U.S. and which is increasing rapidly in incidence because of this epidemic. Availability of a rapid screening test that can be administered at the point of care to all neonates would allow for early intervention, reducing costs of treatment and reducing pain and suffering for this vulnerable and helpless patient population. In addition, neonates who require surgery shortly after birth often endure continuous intravenous infusion of morphine or related compounds, which result in development of the same syndrome, as these infants also become addicted to their prescribed medications. Providing a platform to accurately monitor actual levels of these drugs and their metabolites in such patients would allow better-controlled use of these pain management treatments, personalized to the needs of the individual neonate, reducing the probability of addiction and resulting complications, which include deleterious neurological effects. The purpose of this FastTrack SBIR project is to expand upon our preliminary results and prepare for commercialization. We have already demonstrated that backscattering interferometry can be used in combination with highly-selective DNA aptamers to sensitively and accurately detect opioids and their primary urinary metabolites in one microliter urine samples, in less than a minute after sample introduction into our device. In this program, we will improve this platform by (i) modifying the instrument to reduce cost per test and permit multiplexing; (ii) develop the rest of the assay menu needed to detect all the most commonly abused opioid drugs and their metabolites in these samples; and (iii) test the new point of care instrument and assays versus gold-standard mass spectrometry lab-based tests, using real samples obtained from the target patient population. A highly experienced, collaborative team that includes aptamer and assay development scientists at Base Pair Biotechnologies, backscattering interferometry experts at Vanderbilt University, medical device engineers at BioTex, Inc., a clinician from Vanderbilt University Health Center, and a neonatologist with translational/commercialization experience will work together to achieve these goals. A regulatory expert will advise on assay, software and instrument design for use in hospitals, clinics and other venues in which such tests are likely to be deployed.

项目总结/文摘